Thus, in vitro and in vivo experiments are needed to confirm whether IL-17-producing cells are the targets of HGF and whether IGFBP5 and SCRG1 participate in the treatment of pulmonary fibrosis. Here, IGFBP5 is linked to pulmonary fibrosis.